SED filled unaudited financial statement for 6 months ending in June 30, 2017. There is no mention of Amarantus in it. If AMBS is still working on a deal, hopefully it includes extricating itself from SED and sign an agreement with a company that has real $ and expertise in the biomedical field. SED is in no position to help AMBS. What a waste of time.